Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin E Gore

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Cancer Research|December 3, 2008
Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectorsMohan Hingorani, Christine L White, Andrew Merron, et al.
The Lancet. Oncology|July 21, 2009
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialMartin E Gore, Cezary Szczylik, Camillo Porta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidenceDesiree F Kolomainen, James M G Larkin, Mohammad Badran, et al.
BJU International|January 20, 2011
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysisDebra Josephs, Thomas E Hutson, Charles L Cowey, et al.
Lancet (London, England)|February 16, 2010
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trialMartin E Gore, Clare L Griffin, Barry Hancock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogeneSrinivasan Madhusudan, Ayala Tamir, Nicholas Bates, et al.
Cancer Research|March 17, 2006
10th Biennial Helene Harris Memorial Trust meetingFrances R Balkwill, Alan Ashworth, Robert C Bast, et al.
Oncotarget|April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancerSaeed Rafii, Charlie Gourley, Rajiv Kumar, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2012
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignanciesEleni M Karapanagiotou, Victoria Roulstone, Katie Twigger, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Cancer Research|December 3, 2008
Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectorsMohan Hingorani, Christine L White, Andrew Merron, et al.
The Lancet. Oncology|July 21, 2009
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialMartin E Gore, Cezary Szczylik, Camillo Porta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidenceDesiree F Kolomainen, James M G Larkin, Mohammad Badran, et al.
BJU International|January 20, 2011
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysisDebra Josephs, Thomas E Hutson, Charles L Cowey, et al.
Lancet (London, England)|February 16, 2010
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trialMartin E Gore, Clare L Griffin, Barry Hancock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogeneSrinivasan Madhusudan, Ayala Tamir, Nicholas Bates, et al.
Cancer Research|March 17, 2006
10th Biennial Helene Harris Memorial Trust meetingFrances R Balkwill, Alan Ashworth, Robert C Bast, et al.
Oncotarget|April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancerSaeed Rafii, Charlie Gourley, Rajiv Kumar, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2012
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignanciesEleni M Karapanagiotou, Victoria Roulstone, Katie Twigger, et al.
Pageof 6